This was the stock's fourth consecutive day of losses.

AbbVie Inc (ABBV) stock saw a decline, ending the day at $178.5 which represents a decrease of $-1.03 or -0.57% from the prior close of $179.53. The stock opened at $179.2 and touched a low of $176.18 ...

In a regulatory filing, AbbVie (ABBV) stated, “On January 9, 2025, AbbVie determined that it will record an impairment charge related to the ...

AUSTIN, TX / ACCESSWIRE / January 10, 2025 / Aspira Women's Health Inc. ('Aspira' or the 'Company') (Nasdaq:AWH), a bio-analytical based women's health company focused on the development of ...

LVM Capital Management Ltd. MI lifted its holdings in AbbVie Inc. (NYSE:ABBV – Free Report) by 4.4% in the 4th quarter, ...

Graypoint LLC lessened its stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 7.1% during the 4th quarter, according ...

WALTHAM, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that Keli Walbert will join the Apellis Board of Directors, effective immediately. Ms.

Serna Bio, an AI drug discovery company pioneering RNA-targeting small molecules, today announced the members of its Scientific Advisory Board (SAB). Established in 2021, Serna Bio is a preclinical ...

Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...

AbbVie said it would take a $3.5 billion dollar impairment charge related to the failure of a drug it acquired in its ...

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with ...

The failure of Cerevel's emraclidine in schizophrenia will cost AbbVie an impairment charge of about $3.5 billion, the pharma ...